Defective mismatch repair and benefit from bevacizumab for colon cancer: Findings from NSABP C-08

Kay Pogue-Geile, Greg Yothers, Yusuke Taniyama, Noriko Tanaka, Patrick Gavin, Linda Colangelo, Nicole Blackmon, Corey Lipchik, Seong Rim Kim, Saima Sharif, Carmen Allegra, Nicholas Petrelli, Michael J. O'Connell, Norman Wolmark, Soonmyung Paik

Research output: Contribution to journalArticlepeer-review

40 Citations (Scopus)

Abstract

National Surgical Adjuvant Breast and Bowel Project protocol C-08 tested the worth of adding 1 year of bevacizumab to oxaliplatin-based standard adjuvant chemotherapy regimen in the treatment of stage II/III colon cancer. Although the overall result was negative, the possibility that a molecularly defined subset could benefit from bevacizumab cannot be ruled out. We performed post hoc Cox regression analyses to test for marker-by-treatment interactions for standard pathological features and survival analyses using the Kaplan-Meier method. All statistical tests were two-sided and considered statistically significant at the. 05 level. Patients diagnosed with mismatch repair defective (dMMR) tumors derived statistically significant survival benefit from the addition of bevacizumab (hazard ratio [HR] = 0.52; 95% confidence interval [CI] = 0.29 to 0.94; P =. 02) in contrast with no benefit in patients diagnosed with mismatch repair proficient tumors (HR = 1.03; 95% CI = 0.84 to 1.27; p =. 78; Pinteraction =. 04). Although a post hoc finding, this data suggests that a molecularly defined subset of colon cancer patients may derive clinical benefit from antiangiogenesis agents and underscores the need for independent validation in other clinical trials.

Original languageEnglish
Pages (from-to)989-992
Number of pages4
JournalJournal of the National Cancer Institute
Volume105
Issue number13
DOIs
Publication statusPublished - 2013 Jul 3
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Defective mismatch repair and benefit from bevacizumab for colon cancer: Findings from NSABP C-08'. Together they form a unique fingerprint.

Cite this